The CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study) study demonstrated the clinical benefit of modulating interleukin-1β to reduce future atherosclerotic cardiovascular disease in patients with an elevated level of high-sensitivity c-reactive protein [31]. The gene discussed is CRP; the disease is deep vein thrombosis.